The model of diagnosis-related groups (DRG) used to pay for medical care at the expense of compulsory health insurance in 2022 has certain significant differences compared to 2021. Content and cost of DRG for payment of drug therapy of cancer have been updated, while the lists of international non-proprietary names (INN) and drug therapy regimens have been brought into line with current clinical guidelines. The number of DRG was increased and methodology of cluster analysis was changed. The content of DRG to pay for surgical treatment in the ophtalmology profile was updated by transferring medical services from one group to another based on an updated cost calculation. Formation of DRGs for dermatology and venereology has been revised. Indeed, new DRGs considering not only the diagnosis, but also methods of treatment of dermatoses have been formed. Formation of DRGs for payment of treatment with genetically engineered biological drugs and selective immunosuppressants has been significantly changed. Three DRGs have been allocated for inpatient and day care based on classification criterion «INN of a medicinal product» and the number of injections. An approach to paying for antimicrobial therapy of multidrug-resistant infection was revised. Instead of the previously established patient care complexity coefficient, 3 DRGs in a inpatient care have been allocated. Assigning to this group is based on INN of the drug for antimicrobial therapy. Approaches to coding and payment for botulinum toxin therapy including rehabilitation of patients with diseases of the central nervous system have been changed. New DRGs for payment of immunization against respiratory syncytial virus infection and hospitalizations in delayed post-transplant period after transplantation of hematopoietic stem cells of blood and bone marrow were created. The cost of DRG for speech processor replacement was updated. The list of DRGs with established share of expenses for staff salaries and some other items of expenditures used in calculation of tariffs in monetary terms has been expanded. The lists of reasons for considering a case to be interrupted, as well as payment for treatment cases for two or more DRGs and approaches to the use of patient care complexity coefficients have been updated.